Completed PHASE1 INTERVENTIONAL 14-arm NCT06698926

A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

A Phase 1 First in Human, Single and Multiple Ascending Dose, Food Effect, and Drug-Drug Interaction Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-CLS-616

Sponsor: AbbVie

Conditions Healthy Volunteer

Interventions ABBV-CLS-616 Itraconazole Placebo

Updated 4 times since 2024 Last updated: Jan 14, 2026 Started: Nov 11, 2024 Primary completion: Jan 9, 2026 Completion: Jan 9, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Volunteer, this trial is completed. The trial is conducted by AbbVie and has accumulated 4 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Aug 2025 — Jan 2026 [monthly]

Recruiting PHASE1
Dec 2024 — Aug 2025 [monthly]

Recruiting PHASE1

First recorded

Nov 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie
Calico Life Sciences LLC

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Grayslake, United States